Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …

The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD),
previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A …

Chronic liver disease (CLD) is associated with approximately two million annual deaths
worldwide and is an enormous health burden.[1, 2] The majority of liver-related outcomes …

Background & Aims Liver biopsy is the reference standard for staging and grading
nonalcoholic fatty liver disease (NAFLD), but histologic scoring systems are semiquantitative …

Background Dynamic contrast-enhanced (DCE) photoacoustic (PA) imaging (PAI) is a novel
noninvasive imaging modality that uses the differences in optical absorption of …

Background and Aims Porto‐sinusoidal vascular liver disease (PSVD) is a rare cause of
portal hypertension. PSVD is still often misdiagnosed as cirrhosis, emphasizing the need to …

Distinct structural and dynamic components of portal hyperte... : Hepatology Distinct structural
and dynamic components of portal hypertension in different animal models and human liver …

The development and validation of non-invasive fibrosis tests (NITs) has changed clinical
practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease …

Accurate detection and quantification of hepatic fibrosis remain essential for assessing the
severity of non-alcoholic fatty liver disease (NAFLD) and its response to therapy in clinical …

Current methods of staging liver fibrosis have notable limitations. We investigated the utility
of PET in staging liver fibrosis by correlating liver uptake of 68Ga-labeled fibroblast …